Warfarin embryopathy: fetal manifestationsWAINWRIGHT, Helen; BEIGHTON, Peter.Virchows Archiv. 2010, Vol 457, Num 6, pp 735-739, issn 0945-6317, 5 p.Article

Optimal initial dose adjustment of warfarin in orthopedic patientsLENZINI, Petra A; GRICE, Gloria R; GAGE, Brian F et al.The Annals of pharmacotherapy. 2007, Vol 41, Num 11, pp 1798-1804, issn 1060-0280, 7 p.Article

Warfarin-induced tracheobronchial calcificationTHOONGSUWAN, Nisa; STERN, Eric J.Journal of thoracic imaging. 2003, Vol 18, Num 2, pp 110-112, issn 0883-5993, 3 p.Article

The story of the discovery of heparin and warfarinWARDROP, Douglas; KEELING, David.British journal of haematology. 2008, Vol 141, Num 6, pp 757-763, issn 0007-1048, 7 p.Article

Probable Interaction Between Warfarin and TorsemideBIRD, Jennifer; CARMONA, Carlos.The Annals of pharmacotherapy. 2008, Vol 42, Num 12, pp 1893-1898, issn 1060-0280, 6 p.Article

Warfarin: from bedside to BenchWESSLER, S; GITEL, S.The New England journal of medicine. 1984, Vol 311, Num 10, pp 645-652, issn 0028-4793Article

Influence of the VKORC1 3730 G > A polymorphism on warfarin doseSKOV, Jane; BLADBJERG, Else-Marie; JESPERSEN, Jørgen et al.European journal of clinical pharmacology. 2013, Vol 69, Num 4, pp 1043-1044, issn 0031-6970, 2 p.Article

Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian populationLEE, Soo-Chin; NG, Swee-Siang; NG, Kheng-Siang et al.Clinical pharmacology and therapeutics. 2006, Vol 79, Num 3, pp 197-205, issn 0009-9236, 9 p.Article

WARFARIN THERAPY : INFLUENCE OF PHARMACOGENETIC AND ENVIRONMENTAL FACTORS ON THE ANTICOAGULANT RESPONSE TO WARFARINSIGURET, Virginie; PAUTAS, Eric; GOUIN-THIBAULT, Isabelle et al.Vitamins and hormones. 2008, Vol 78, pp 247-264, issn 0083-6729, 18 p.Article

Fluorescence Enhancement of Warfarin Induced by Interaction with β-CyclodextrinVASQUEZ, Jacob M; VU, Andrew; SCHULTZ, Jerome S et al.Biotechnology progress. 2009, Vol 25, Num 4, pp 906-914, issn 8756-7938, 9 p.Conference Paper

Reversible endotension associated with excessive warfarin anticoagulationIYER, Vikram S; MACKENZIE, Kent S; CORRIVEAU, Marc-Michel et al.Journal of vascular surgery. 2007, Vol 45, Num 3, pp 600-602, issn 0741-5214, 3 p.Article

The influence of VKORC1 3730 G > A polymorphism on warfarin dose: replyCINI, Michela; LEGNANI, Cristina; COSMI, Benilde et al.European journal of clinical pharmacology. 2013, Vol 69, Num 4, issn 0031-6970, p. 1045Article

Solving the mystery of excessive warfarin-induced bleeding: A personal historical perspectiveHIRSH, Jack.Thrombosis and haemostasis. 2014, Vol 112, Num 5, pp 853-856, issn 0340-6245, 4 p.Article

The impact of VKORC1-1639G > A genetic polymorphism upon warfarin dose requirement in different ethnic populationsBO JIN; YONG HONG; JUN ZHU et al.Current medical research and opinion. 2014, Vol 30, Num 8, pp 1505-1511, issn 0300-7995, 7 p.Article

Influence of ORM1 polymorphisms on the maintenance stable warfarin dosageLIAN SHENG WANG; JING JING SHANG; ZHI LI et al.European journal of clinical pharmacology. 2013, Vol 69, Num 5, pp 1113-1120, issn 0031-6970, 8 p.Article

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patientsLAL, Suman; SANDANARAJ, Edwin; SRINIVASA RAO JADA et al.British journal of clinical pharmacology. 2008, Vol 65, Num 2, pp 260-264, issn 0306-5251, 5 p.Article

Feasibility of Implementing a Comprehensive Warfarin Pharmacogenetics ServiceNUTESCU, Edith A; DROZDA, Katarzyna; KADKOL, Shrihari S et al.Pharmacotherapy. 2013, Vol 33, Num 11, pp 1156-1164, issn 0277-0008, 9 p.Article

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarinTEH, L. K; LANGMIA, I. M; FAZLEEN HASLINDA, M. H et al.Journal of clinical pharmacy and therapeutics (Print). 2012, Vol 37, Num 2, pp 232-236, issn 0269-4727, 5 p.Article

Pathology Consultation on Warfarin Pharmacogenetic TestingSTACK, Gary.American journal of clinical pathology. 2011, Vol 135, Num 1, pp 13-19, issn 0002-9173, 7 p.Article

Plasma S/R ratio of warfarin co-varies with VKORC1 haplotypeOSMAN, Abdimajid; ENSTRÖM, Camilla; LINDAHL, Tomas L et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 3, pp 293-296, issn 0957-5235, 4 p.Article

INTRAVASCULAR CLEARANCE OF ENDOTOXIN IN WARFARIN-TREATED RABBITS. THE INFLUENCE OF IMMUNE SERUM ON CLEARANCE AND DISTRIBUTION = LA DISPARITION DE L'ENDOTOXINE DU SYSTEME VASCULAIRE CHEZ LES LAPINS PREALABLEMENT TRAITES PAR LA WARFARINE. INFLUENCE DE L'IMMUNSERUM SUR LA DISPARITION ET LA REPARTITION1972; ACTA PATHOL. MICROBIOL. SCAND., B; DANEM.; DA. 1972; VOL. 80; NO 3; PP. 420-430; BIBL. 23REF.Serial Issue

Coagulating evidence for a new genetic link to drug responsiveness to warfarin therapyROSS, C. J. D.Clinical genetics. 2005, Vol 68, Num 4, pp 327-329, issn 0009-9163, 3 p.Article

Effect of age upon the induction and maintenance of anticoagulant with warfarinGLADMAN, J. R. F; DOLAN, G.Postgraduate medical journal. 1995, Vol 71, Num 833, pp 153-155, issn 0032-5473Article

Randomized trial of lottery-based incentives to improve warfarin adherenceKIMMEL, Stephen E; TROXEL, Andrea B; LOEWENSTEIN, George et al.The American heart journal. 2012, Vol 164, Num 2, pp 268-274, issn 0002-8703, 7 p.Article

Association of warfarin dose with genes involved in its action and metabolismWADELIUS, Mia; CHEN, Leslie Y; ERIKSSON, Niclas et al.Human genetics. 2007, Vol 121, Num 1, pp 23-34, issn 0340-6717, 12 p.Article